Romie Lane Dental Group, Lewis H Richardson, DDS, Inc Receives Exclusive ACE(tm) Certification in the Diagnosis and Treatment of Periodontal Disease
Released on = August 13, 2007, 5:25 pm
Press Release Author = Lewis H. Richardson
Industry = Healthcare
Press Release Summary = Salinas, CA - August 9, 2007 - Romie Lane Dental Group, Lewis H. Richardson, DDS, Inc. recently received ARESTIN® Certified Expert (ACET) certification after completing comprehensive training on the diagnosis and treatment of periodontal disease.
Press Release Body = Romie Lane Dental Group, Lewis H. Richardson, DDS, Inc. Receives Exclusive ACET Certification in the Diagnosis and Treatment of Periodontal Disease
Salinas, CA - August 9, 2007 - Romie Lane Dental Group, Lewis H. Richardson, DDS, Inc. recently received ARESTIN® Certified Expert (ACET) certification after completing comprehensive training on the diagnosis and treatment of periodontal disease.
The exclusive ACET certification is important to residents of Salinas because periodontal disease is the most common chronic bacterial infection in adults, affecting 35.7 million Americans,1 and is the leading cause of adult tooth loss.2 In addition, the Surgeon General has issued a warning3 regarding the possible relationship between periodontal disease and a variety of medical conditions, including cardiovascular disease, diabetes, and osteoporosis.
"Knowing the negative impact periodontal disease that is left untreated can have on the oral heath and general health of my patients prompted me to enroll in the ACET certification training," said Dr. Richardson. "This important and comprehensive periodontal disease diagnosis and treatment training program enables me to continue providing my patients with the highest standard of care available."
ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg is a locally administered antibiotic (LAA) manufactured by OraPharma, Inc. Clinical studies have proven that ARESTIN® used as an adjunct to scaling and root planing (SRP) is more effective than SRP alone in eliminating periodontal pathogens.4
SRP is a manual procedure that is performed by a dentist or registered dental hygienist, whereby bacterial pathogens residing in the plaque and tartar are removed from below the gum line while smoothing the tooth's root surfaces to promote healing and prevent plaque from again taking hold.
During SRP, many dentists prescribe or administer an LAA to treat the periodontal infection and promote healing. One such LAA is OraPharma's ARESTIN®. According to Dr. Richardson, "ARESTIN® is an effective antibiotic that kills the bacteria that cause periodontal disease."
In order to earn ACET certification, Dr. Richardson was trained and tested in the following areas: accurate diagnosis of periodontal disease, effective treatment protocol, accurate insurance coding, the benefits of using LAAs, staff and patient education, encouraging patient compliance, patient monitoring, and the possible systemic health risks of untreated periodontal disease.
About Dental Office:
For 37 years, Dr. Richardson has been creating beautiful smiles with a personal touch. A native of Ohio, he attended Ohio State University from 1962 to 1970 receiving his dental degree. Upon graduating he entered the United States Navy. Dr. Richardson spent two years in San Diego caring for the dental needs of his fellow military men and women. After leaving the armed services, he moved to the Monterey Bay area in 1972 and opened a dental practice. Dr. Richardson has been working to develop an excellent, family dental practice ever since.
Over the past 37 years, he has spent thousands of hours in seminars, and other continuing education courses in order to stay current on advances in the continuously changing dental field. Dr. Richardson is an active member of the American Dental Association, the California Dental Association and the Monterey Bay Dental Society, where he served as president in 1984-1985. Dr. Richardson has also served the community as a past president of the Salinas Area United Way.
About OraPharma, Inc.: OraPharma, Inc. is a specialty pharmaceutical company that discovers, develops, and commercializes therapeutics for the treatment of periodontal disease at various phases of progression. ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg (www.arestin.com) is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program which includes good oral hygiene, and scaling and root planing. ARESTIN® contains minocycline, a tetracycline derivative, and therefore should not be used in children and in pregnant or nursing women. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth. The most common treatment-emergent adverse events were headache (9.0%), infection (7.6%), flu syndrome (5.0%), and pain (4.3%). These occurred at a similar rate to SRP and SRP + placebo.
1. Albandar JM, Brunelle JA, Kingman A. Destructive periodontal disease in adults 30 years of age and older in the United States, 1988-1994. J Periodontol 1999;70:13-29. 2. Lewis C. Fighting gum disease: how to keep your teeth. FDA Consum 2002;36:16-22. 3. US Department of Health and Human Services. Oral Health in America: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of Health; 2000. 4. Goodson JM. Antimicrobial Efficacy of Arestin in Periodontitis Therapy. Presented at the 35th Annual Meeting of the American Association for Dental Research; March 8-11, 2006; Orlando, FL.
The decision to administer ARESTIN® is made solely by the healthcare professional.
2025
